Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

Completed · Phase 4

Conditions studied: Pneumonia, Ventilator-Associated

In brief

Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. The purpose of this protocol is to directly compare linezolid and vancomycin specifically for MRSA VAP.

Key facts

Study ID

NCT00572559

Run by

Pfizer

People needed

149

Starts

2002-11-01

Expected to finish

2005-01-01

Last updated by the study team

2010-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient must have or be suspected of having a ventilator-associated pneumonia (VAP) due to MRSA.
• Patient must be hospitalized for at least 5 days, must be ventilator-dependent ≥ 48 hours prior to screen/baseline, and anticipated to remain on the ventilator for 72 hours after enrollment so follow-up BAL can be performed.
• Clinical picture compatible with pneumonia (acquired during ventilation)
• Chest X Ray at baseline/screen or within 24 hours of initiation of therapy must be consistent with diagnosis of pneumonia

You may not qualify if…

• Hypersensitivity to linezolid, vancomycin, or one of the excipients in any of these drug formulations.
• Infections due to gram-positive organisms known to be resistant to either of the study drugs.
• Any antibiotic used in the treatment of MRSA, such as vancomycin, TMP/SMX, rifampin, or linezolid, for more than 48 hours prior to patient's enrollment into the study.
• Patients with neutropenia, AIDS, lymphoma or anticipated chemotherapy.
• Patients who have long-term tracheostomy (for more than 60 days). Acute tracheostomy patients are allowed.

Where it is running

• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Palm Springs, California, United States
• Pfizer Investigational Site — Rancho Mirage, California, United States
• Pfizer Investigational Site — Redlands, California, United States
• Pfizer Investigational Site — Sacramento, California, United States
• Pfizer Investigational Site — Sacramento, California, United States
• Pfizer Investigational Site — Norwalk, Connecticut, United States
• Pfizer Investigational Site — Waterbury, Connecticut, United States
• Pfizer Investigational Site — Waterbury, Connecticut, United States
• Pfizer Investigational Site — Augusta, Georgia, United States
• Pfizer Investigational Site — Decatur, Georgia, United States
• Pfizer Investigational Site — North East Atlanta, Georgia, United States
• Pfizer Investigational Site — North East Atlanta, Georgia, United States
• Pfizer Investigational Site — North East Atlanta, Georgia, United States
• Pfizer Investigational Site — ‘Ewa Beach, Hawaii, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Peoria, Illinois, United States
• Pfizer Investigational Site — Peoria, Illinois, United States
• Pfizer Investigational Site — Peoria, Illinois, United States
• Pfizer Investigational Site — Lexington, Kentucky, United States
• Pfizer Investigational Site — Louisville, Kentucky, United States
• Pfizer Investigational Site — Buffalo, New York, United States
• Pfizer Investigational Site — Cortland Manor, New York, United States
• Pfizer Investigational Site — Jamaica, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.